Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetylpyridinium Chloride for Sarcopenia Prevention
NCT02297997Phase 1Completed
- Sponsor
- Seoul National University Hospital
- Start
- Nov 2014
- Primary completion
- Nov 2015
- Modality
- Conventional Liposomes, Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of cetylpyridinium chloride in Sarcopenia (5 arms), sponsored by Seoul National University Hospital. Primary endpoints: Procollagen type III N-terminal peptide at 4 weeks, Myostatin at 4 weeks and 3 more. Started Nov 2014; status: completed.
02
Drugs
cetylpyridinium chloride
03
Conditions
Sarcopenia
Beyond the preview
Go deeper on NCT02297997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02297997.